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Multiple studies in hyperthermic oncology testify 
the enhancing efficacy of combination or multimodali­
ty therapy of cancer patients by application of high 
temperature (40–43 °C for whole­body exposure and 
42–47 °C for local treatment). Hyperthermia has been 
shown to be a powerful modifying factor that increases 
tumor sensitivity to both radio­ and chemotherapy 
[1–6].
Thermal enhancement of cytotoxic effects for 
many anticancer drugs has been observed in diffe rent 
experimental systems. The mechanisms involved in 
the interaction of chemotherapy and hyperthermia 
are depended on the particular chemotherapeutic 
agent and thought to be related to an increase in drug 
uptake, expand of DNA damage and inhibition of DNA 
repair [1–3, 7]. In vitro drug­induced cell killing usu­
ally increased with temperature from 40 °C to 45 °C 
and maximal cytotoxicity occurred when the drug was 
scheduled simultaneously with hyperthermia. In vivo 
the therapeutic efficacy of the thermotherapy was 
maximized at mild temperature (40.5–43 °C) and the 
greatest potentiation occurred when the two modali­
ties were administered close together [2, 6, 7].
Despite several experimental studies on the inter­
action of hyperthermia with chemotherapeutic drugs 
data concerning treatment efficiency are often con­
flicting. The use of various cell lines, different treatment 
schemes and differing end points complicates the 
interpretation of research findings. Drug concentration 
and drug exposure time are also of great importance. 
Furthermore, in vitro and vivo results often differ due 
to physiology factors of tumor tissue such as micro­
circulation, pH and oxygenation.
Alkylating agents melphalan, cyclophosphamide 
and ifosfamide were shown to be the most effective 
drug at moderately elevated temperatures for many 
types of tumors, effectiveness of cisplatin or oxali­
platin was less pronounced [8, 9, 10]. Hyperthermia 
was proved to enhance the sensitivity of human tumor 
cells to doxorubicin [7, 11, 12], vincristine [12] and 
carboplatin [13, 14], whereas the efficacy of etoposide 
is only slightly influenced by additional application 
of heat [15, 16] or decreased [17]. However it was 
demonstrated that appropriately scheduled hyper­
thermia and etoposide treatments result in increased 
etoposide­induced death of human leukemia cells 
[18]. Simultaneous application of gemcitabine and 
heat led to decreased cytotoxicity [19, 20], had not the 
influence on cytotoxicity [12] or augmented cytotoxic 
effect of drug [10, 21, 22]. There are also contradictory 
reports as to the interaction of hyperthermia and the 
taxanes [10, 23–28]. 
Therefore it is important to compare in equal treat­
ment conditions the impact of hyperthermia on the 
action of the main chemotherapeutic drugs currently 
used for cancer treatment. In this study we investigated 
the differences in HeLa tumor cell culture growth after 
incubation with different anticancer drugs at a tem­
perature of 37 °C or 42 °C.
MATERIALS AND METHODS
Chemotherapeutic drugs. The drugs investiga­
ted were ifosfamide (holoxan, Baxter Oncology Gmbx, 
Germany), doxorubicin (doxorubicin hydrochloride, 
RUE “Belmedpreparaty”, Belarus), carboplatin 
(carboplatin­LENS, Veropharm, Russia), oxaliplatin 
(eloxatin, Sanofi­Synthelabo, France), vinorelbin 
(neocitec, Labinca, Argentina), etoposide (etoposide­
LENS, Veropharm, Russia), docetaxel (docetal, Dabur 
Pharma Ltd., India), gemcitabine (gemzar, “Eli Lilly”, 
USA). Just before use, the drugs were diluted with 
culture medium.
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Cell culture. HeLa cells (human cervical carci­
noma) were obtained from the cell culture collection of 
Research Institute of Epidemiology and Microbiology 
(RIEM, Minsk, Belarus). The cells were cultured as 
a monolayer in culture flasks covered with 199 medium 
(RIEM) supplemented with 10% fetal calf serum (RIEM) 
and 100 µg/ml kanamycin.
Cell treatment. One day before the drug treat­
ment, cell monolayer was detached from the culture 
flasks with 0.02% versen (DIALEK, Belarus) and 
plated at a concentration of 2 × 105 cells/flask. All 
the experiments were carried out on exponentially 
growing cells. On the day of the experiment, 100 µl of 
each drug dilutions were added into the flasks with cell 
monolayer and then the cells were incubated in water 
bath at 37.0 °C ± 0.1 °C or 42.0 °C ± 0.1 °C for 60 min. 
Treated and control cells were cultured for additional 
48 h, then cell monolayers were versenized and viable 
cells were counted using trypan­blue exclusion on 
a haemocytometer. The mean ± standard deviation 
was calculated from three experiments.
To differentiate between cytostatic and cytotoxic 
effects, the number of viable cells after the treatment 
was compared with the initial cell number before any 
treatment. Percentage of viable cells above the initial 
cell number denoted a cytostatic effect, whereas those 
below showed cytotoxicity [23]. The percentages of 
viable cells for each treatment were calculated from 
100 × [(Nt–No) / (Nk–No)], if Nt was greater than or 
equal No, or 100 × [(Nt–No) / No], if Nt was less than No 
(Nt — cell number in treated cultures with chemothera­
peutic drug and/or hyperthermia; Nk — cell number in 
control cultures that had not been exposed to chemo­
therapeutic drugs or hyperthermia; No — initial cell 
number before the treatment).
The values of IC50 and IC90, concentrations of each 
drug required for a 50% and 90% reduction in cell 
number relative to control value, and LC50, concen­
tration of drug required for a 50% reduction in cell 
number relative to initial value before the treatment, 
were determined for each experiment using regression 
analysis of the data received. Thermal enhancement 
ratios for inhibition of cell proliferation and cell killing 
for each chemotherapeutic drug were calculated as 
IC50, IC90, or LC50 for drug alone divided by IC50, IC90, 
or LC50 for drug combined with hyperthermia.
RESULTS AND DISCUSSION
The survivals of exponentially growing HeLa cells 
exposed to various concentration of ifosfamide doxo­
rubicin, carboplatin, docetaxel, vinorelbine, etoposide, 
oxaliplatin or gemcitabine at 37 °C or 42 °C are shown 
in Figure. These data demonstrate that cell number 
reduced with increasing concentrations of chemother­
apeutic agents. All used drugs demonstrated the dose­
dependent enhancement of cytotoxicity at elevated 
temperature — the decrease of cell number at 42 °C 
was more pronounced than at 37 °C. It must be noted 
the heat treatment alone did not alter significantly cell 
number causing only 10–20% growth inhibition.
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Figure. Dose­response curves for HeLa cells treated with ifosfa­
mide, doxorubicin, carboplatin, oxaliplatin, vinorelbine, etoposide, 
docetaxel or gemcitabine at 37 °С or 42 °С. The cells were incubated 
with different concentration of anticancer drug for 1 h at 37 °C or 
42 °C and counted 48 h later. Each data point represents the mean 
of three separate experiments. Bars are standard errors
The parameters of cytostatic (IC50 and IC90) and 
cytotoxic (LC50) effects of chemotherapeutic drugs 
at 37 °C and 42 °C are presented in Table. The data 
obtained testify the enhanced efficiency at elevated 
temperature to a greater or lesser extent of all the 
drugs under investigation. So, by IC50 and IC90 crite­
ria, hyperthermia caused significant enhancement of 
cell culture growth inhibition induced by ifosfamide, 
carboplatin, vinorelbine, oxaliplatin, with thermal en­
hancement ratio exceeded 4. The values of IC50 and 
IC90 decreased actually for vinorelbine 5.5­fold and 
for oxaliplatin 7.2­fold after combination with heat. 
To a lesser degree hyperthermia enhanced cytostatic 
effect of doxorubicin and gemcitabine, with thermal 
enhancement ratio exceeded 2. The differences in 
IC50 and IC90 for docetaxel and etoposide were not 
significant statistically. By LC50 criterion, statistically 
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significant enhancement of drug­mediated cytotoxici­
ty under elevated temperature was observed only for 
carboplatin, vinorelbine, docetaxel and oxaliplatin, 
with thermal enhancement ratio for cell death did not 
exceed 1.4. Thus, thermal enhancement for drug­
mediated inhibition of cell proliferation by combination 
of chemotherapeutic drugs with hyperthermia was 
more pronounced than for drug­mediated cell killing. 
The most efficient chemotherapeutic drugs in HeLa 
cells at elevated temperature 42 °C were ifosfamide, 
carboplatin, vinorelbine and oxaliplatin.
In this study we investigated in cell culture the 
action of eight anticancer drugs in broad range of 
concentrations to describe their both cytostatic and 
cytotoxic effects. To quantitatively evaluate the impact 
of the hyperthermia on the chemosensitivity of tumor 
cells we compared the values of IC50, IC90, and LC50 
for dose­response curves of HeLa cell culture treated 
with chemotherapeutic drugs alone or in combination 
with heat. It was found that interaction of hyperther­
mia and simultaneous chemotherapy depends on 
the drug concentration. At low doses of chemothera­
peutic agents that exerted mainly cytostatic effect it 
was shown synergistic interaction with heat for all the 
drugs under investigation except for docetaxel and 
etoposide, whereas at high doses of drugs that exerted 
predominantly cytotoxic action their interaction with 
heat was only additive.
Thermal enhancement of the cytostatic effect we 
have observed in this study in vitro may be of impor­
tance under in vivo conditions where events inducing 
the delay of tumor growth are expected to be cytostatic 
rather than cytotoxic [10]. We believe the data present 
in this study have clinical implication having recently 
begun animal tumor experiments to evaluate efficiency 
of the same chemotherapy in protocols with whole­
body hyperthermia. 
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ЭФФЕКТ УСИЛЕНИЯ АКТИВНОСТИ ПРОТИВООПУХОЛЕВЫХ 
ПРЕПАРАТОВ ПРИ ПОВЫШЕНИИ ТЕМПЕРАТУРЫ IN VITRO
Цель: изучить in vitro влияние повышенной температуры (42 °C в течение 60 мин) на действие противоопухолевых препаратов: 
доксорубицина, винорельбина, карбоплатина, ифосфамида, этопозида, оксалиплатина, доцетаксела и гемцитабина. Методы: 
культуру опухолевых клеток HeLa через 24 ч после рассева инкубировали в течение 60 мин с различными концентрациями 
химиотерапевтических препаратов при температуре 37 °C или 42 °C. Спустя 48 ч подсчитывали количество живых клеток во 
флаконах, используя гемоцитометр и метод исключения красителя трипанового синего. Результаты: гипертермия сама по 
себе вызывала 10–20% угнетение роста культуры клеток. У всех исследованных химиотерапевтических препаратов отмечали 
эффект усиления при повышенной температуре. Коэффициент теплового усиления в отношении клеточной пролиферации 
для оксалиплатина, винорельбина, карбоплатина и ифосфамида превысил 4,0, для доксорубицина и гемцитабина — 2,0. 
Коэффициент теплового усиления в отношении гибели клеток не превышал 1,4. Выводы: синергизм гипертермии 
и химиотерапевтических препаратов продемонстрирован для оксалиплатина, винорельбина, карбоплатина, ифосфамида, 
в меньшей степени — для доксорубицина и гемцитабина. Усиление цитостатического эффекта противоопухолевых препаратов 
под действием гипертермии было более выраженным, чем их цитотоксического эффекта.
Ключевые слова: гипертермия, противоопухолевые препараты, клетки HeLa, коэффициент теплового усиления.
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